Hypoxia-inducible factor 1 and Tumor necrosis factor signaling pathways (HIF-1/TNF)

The Hypoxia-Inducible Factor 1 (HIF-1) and Tumor Necrosis Factor (TNF) signaling pathways are two fundamental regulatory systems that govern cellular responses to environmental stress and immune challenges. HIF-1 is a heterodimeric transcription factor that acts as the primary mediator of the adaptive response to hypoxia, regulating genes involved in angiogenesis, metabolic reprogramming, and erythropoiesis (Semenza, 2012, PubMed). The TNF pathway is a central pro-inflammatory cascade triggered by the cytokine TNF-alpha, which regulates immune cell activation, survival, and programmed cell death (Aggarwal, 2003, Nature Reviews Immunology). These two pathways frequently intersect in pathological conditions such as cancer and chronic inflammation; for instance, TNF-alpha can induce HIF-1alpha expression under normoxic conditions via the NF-kappaB pathway, linking inflammatory signaling to the hypoxic response (Hellwig-Bürgel et al., 2005, Blood). While both pathways contain numerous druggable targets, such as TNF-alpha itself or HIF prolyl hydroxylases, they are distinct biological entities rather than a single therapeutic target. Consequently, clinical strategies typically involve specific inhibitors or stabilizers of individual components within these broader signaling networks.

Other names

HIF-1 signaling pathwayTNF signaling pathwayHypoxia-inducible factor 1-alpha signalingTumor necrosis factor-alpha signalingHIF-1 and TNF-alpha crosstalk

TNF inhibitors (e.g., adalimumab) bind to and neutralize soluble and membrane-bound TNF-alpha to prevent its interaction with TNFR1 and TNFR2, thereby suppressing downstream pro-inflammatory cascades. HIF prolyl hydroxylase inhibitors (e.g., roxadustat) stabilize HIF-alpha subunits by inhibiting the enzymes responsible for their degradation under normoxic conditions, which promotes the transcription of erythropoietin and other hypoxia-responsive genes. HIF-2 alpha inhibitors (e.g., belzutifan) specifically block the dimerization of HIF-2 alpha with HIF-1 beta, preventing the transcription of genes that drive tumor growth in certain cancers.